The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
LevinV.A., EdwardsM.S., WrightD.C.Modified procarbazine, CCNU and vincristine (PCV-3) combination chemotherapy in the treatment of malignant brain tumors. Cancer Treat Rep.1980; 64(2-3): 237–241.
2.
LevinV.A., SilverP., HanniganJ., Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys.1990; 18(2): 321–324.
3.
LevinV.A., WaraW.H., DavisR.L.Phase III comparison of BCNU and the combination of procarbazine, CCNU and vincristine administered after radiotherapy with hydroxyurea for malignant glioma. J Neurosurg.1985; 63(2): 218–223.
4.
CairncrossJ.G., MacdonaldD.R.Successful chemotherapy for recurrent malignant oligodendrogliomas. Ann Neurol.1988; 23(4): 360–364.
5.
CairncrossJ.G., MacdonaldD.R., RamsayD.A.Aggressive oligodendroglioma: A chemosensitive tumor. Neurosurgery.1992; 31(1): 78–82.
6.
GlassJ., HochbergF.H., GruberM.L.The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy. J Neurosurg.1992; 76(5): 741–745.
7.
KyritsisA.P., YungW.K., BrunerJ.The treatment of anaplastic oligodendrogliomas and mixed gliomas. Neurosurgery.1993; 32(3): 365–370.
8.
LevinV.A., PradosM.R., WaraW.M.Radiation therapy and bromodeoxyuridine chemotherapy followed by procarbazine, lomustine, and vincristine for the treatment of anaplastic gliomas. Int J Radiat Oncol Biol Phys.1995; 32(1): 75–83.
9.
SoffettiR., RudaR., BradacG.B.PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. Neurosurgery.1998; 43(5): 1066–1073.
10.
van den BentM.J., KrosJ.M., HeimansJ.J.Response rate and prognostic factors of recurrent oligodendroglioma treated with PCV chemotherapy. Neurology.1998; 51(4): 1140–1145.
11.
PaleologusN.A., MacdonaldD.R., VickN.A.Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma. Neurology.1999, 53(5): 1141–1143.
12.
StrefferJ., SchabetM., BambergM.A role for preirradiation PCV chemotherapy for oligodendroglial brain tumors. J Neurol.2000; 247(4): 297–302.
13.
LevinV.A., YungW.K., BrunerJ.Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas. Int J Radiat Oncol Biol Phys.2002; 53(1): 58–66.
14.
StegeE.M., KrosJ.M., de BruinH.G.Successful treatment of low-grade olgodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine. Cancer.2005; 103(4): 802–809.
15.
van den BentM.J., CarpentierA.F., BrandesA.A.Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: A randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol.2006; 24(18): 2715–2722.
16.
LebrunC., FontaineD., BourgV.Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas with PCV chemotherapy. Eur J Neurol.2007; 14(4): 391–398.
17.
WickW., HartmannC., EngelC.NOA-04 Randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol.2009; 27(35): 5874–5880.
18.
ShawE.G., WangM., CoonsS.W.Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: Initial results of RTOG 9802. J Clin Oncol.2012; 30(25): 3065–3070.
19.
van den BentM.J., BrandesA.A., TaphoornM.J.Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: Long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol.2013; 31(3): 344–350.
20.
BucknerJ.C., ShawE.G., PughS.L.Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. N Engl J Med.2016; 374(14): 1344–1355.
21.
CairncrossG., MacdonaldD., LudwinS.Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol.1994; 12(10): 2013–2021.
22.
KirbyS., MacdonaldD., FisherB.Pre-radiation chemotherapy for malignant glioma in adults. Can J Neurol Sci.1996; 23(2): 123–127.
23.
MasonW.P., KrolG.S., DeAngelisL.M.Low-grade oligodendroglioma responds to chemotherapy. Neurology.1996; 46(1): 203–207.
24.
BucknerJ.C., GesmeD.Jr, O'FallonJ.R.Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: Efficacy and associations with chromosomal abnormalities. J Clin Oncol.2003; 21(2): 251–255.
25.
CairncrossG., BerkeyB., ShawE.Phase III trial of chemotherapy plus radiotherapy versus radiotherapy alone for pure and mixed anaplastic oligodendroglioma (RTOG 9402): Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol.2006; 24(18): 2707–2714.
26.
GutinP.H., WilsonC.B., KumarA.R.V.Phase II study of procarbazine, CCNU and vincristine combination chemotherapy in the treatment of malignant brain tumors. Cancer.1975; 35(5): 1398–1404.
27.
KimL., HochbergF.H., ThorntonA.F.Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas. J Neurosurg.1996; 85(4): 602–607.
28.
KällénK., GeijerB., MalmströmP.Quantitative 201Tl SPET imaging in the follow-up of treatment for brain tumour: A sensitive tool for the early identification of response to chemotherapy?Nucl Med Commun.2000; 21(3): 259–267.
29.
Sandberg-WollheimM., MalmströmP., Strömblad. A randomized study of chemotherapy with procarbazine, vincristine, and lomustine with and without radiation therapy for astrocytoma grades 3 and/or 4. Cancer.1991; 68(1): 22–29.
30.
Medical Research Council Brain Tumor Working Party.Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: A Medical Research Council trial. J Clin Oncol.2001; 19(2): 509–518.
31.
MurphyC., PicklesT., KnowlingM.Concurrent modified PCV chemotherapy and radiotherapy in newly diagnosed grade IV astrocytoma. J Neurooncol.2002; 57(3): 215–220.
32.
CornettaK., CroopJ., DropchoE.A pilot study of dose-intensified procarbazine, CCNU, vincristine for poor prognosis brain tumors utilizing fibronectin-assisted, retroviral-mediated modification of CD34+ peripheral blood cells with O6-methylguanine DNA methyltransferase. Cancer Gene Ther.2006; 13(9): 886–895.
BaschE., PrestrudA.A., HeskethP.J.Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol.2011; 29(31): 4189–4198.
37.
HeskethP.J., BohlkeK., LymanG.H.Antiemetics: American Society of Clinical Oncology. Focused Guideline Update. J Clin Oncol.2016; 34(4): 381–386.
GelingO., EichlerH.G.Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol.2005; 23(6): 1289–1294.
40.
TerreyJ.P., AaproM.S.The activity of granisetron in patients who had previously failed ondansetron antiemetic therapy. Eur J Clin Res.1996; 8: 281–288.
41.
CarmichaelJ., KeizerH.J., CupissolD., MilliezJ., ScheidelP., SchindlerA.E.Use of granisetron in patients refractory to previous treatment with antiemetics. Anticancer Drugs.1998; 9(5): 381–385.
42.
de WitR., de BoerA.C., vd LindenG.H., StoterG., SparreboomA., VerweijJ.Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer.2001; 19: 85(8): 1099–1101.
43.
SmithI.E.A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy. The Granisetron Study Group. J Cancer Res Clin Oncol.1993; 119(6): 350–354.
44.
SoukopM.A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Granisetron Study Group. Support Care Cancer.1994; 2(3): 177–183.
45.
SmithT.J., BohlkeK., LymanG.H.Recommendations for the use of white blood cell growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol.2015; 33(28): 3199–3212.
KintzelP.E., DorrR.T.Anticancer drug renal toxicity and elimination: Dosing guidelines for altered renal function. Cancer Treatment Rev.1995; 21(1): 33–64.
52.
AronoffG.R., BennettW.M., BernsJ.S., SmoyerW.E.Drug Prescribing in Renal Failure.5th ed.Philadelphia: American College of Physicians; 2007.
